T. Rowe Price Associates
CTXR icon

T. Rowe Price Associates’s Citius Pharmaceuticals CTXR Stock Holding History

T. Rowe Price Associates’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,209
Closed -$28K – 2945
2024
Q1 		$28K Buy
1,209
+84
+7% +$1.53K ﹤0.01% 2917
2023
Q4 		$22K Buy
1,125
+125
+13% +$2.37K ﹤0.01% 2869
2023
Q3 		$18K Sell
1,000
-940
-48% -$22.3K ﹤0.01% 2854
2023
Q2 		$59K Buy
1,940
+1,000
+106% +$32.9K ﹤0.01% 2785
2023
Q1 		$28K Buy
940
+44
+5% +$1.27K ﹤0.01% 2836
2022
Q4 		$18K Hold
896
– – ﹤0.01% 2879
2022
Q3 		$28K Hold
896
– – ﹤0.01% 2893
2022
Q2 		$21K Buy
896
+60
+7% +$1.65K ﹤0.01% 2925
2022
Q1 		$37K Buy
836
+132
+19% +$5.21K ﹤0.01% 2937
2021
Q4 		$27K Sell
704
-80
-10% -$3.63K ﹤0.01% 2954
2021
Q3 		$40K Buy
784
+24
+3% +$1.2K ﹤0.01% 2911
2021
Q2 		$66K Buy
760
+344
+83% +$20.7K ﹤0.01% 2881
2021
Q1 		$19K Hold
416
– – ﹤0.01% 2840
2020
Q4 		$11K Buy
+416
New +$10.8K ﹤0.01% 2663

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's CTXR Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 1,209 shares — an estimated $28K sold.

T. Rowe Price Associates first reported a position in CTXR in Q4 2020 and held it in 14 quarters. The position peaked at $66K in Q2 2021. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,209 Citius Pharmaceuticals shares in Q2 2024, an estimated $28K.
  • T. Rowe Price Associates first reported a position in Citius Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • T. Rowe Price Associates's Citius Pharmaceuticals position peaked at $66K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.